Sotera Health (NASDAQ:SHC) Price Target Raised to $16.00 at JPMorgan Chase & Co.

Sotera Health (NASDAQ:SHC) had its price objective upped by JPMorgan Chase & Co. from $14.00 to $16.00 in a research note released on Wednesday,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other equities analysts have also weighed in on SHC. Wall Street Zen upgraded Sotera Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Barclays upped their price target on shares of Sotera Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday. Piper Sandler upped their price target on shares of Sotera Health from $15.00 to $17.00 and gave the company a “neutral” rating in a research note on Wednesday. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Sotera Health in a report on Friday, October 31st. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Sotera Health presently has a consensus rating of “Hold” and a consensus target price of $17.40.

Sotera Health Stock Down 3.8%

SHC opened at $15.81 on Wednesday. The stock has a market cap of $4.49 billion, a PE ratio of 83.21 and a beta of 1.82. The company has a current ratio of 2.38, a quick ratio of 2.23 and a debt-to-equity ratio of 3.87. The stock’s fifty day simple moving average is $16.12 and its 200 day simple moving average is $13.71. Sotera Health has a 1-year low of $9.53 and a 1-year high of $17.78.

Sotera Health (NASDAQ:SHC) last announced its earnings results on Friday, August 8th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.17 by $0.03. The business had revenue of $294.34 million during the quarter, compared to the consensus estimate of $275.81 million. Sotera Health had a net margin of 4.82% and a return on equity of 43.69%. Sotera Health’s revenue was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.19 EPS. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. As a group, research analysts expect that Sotera Health will post 0.61 earnings per share for the current year.

Insider Activity

In other Sotera Health news, insider Michael P. Rutz sold 126,611 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $16.38, for a total value of $2,073,888.18. Following the transaction, the insider directly owned 450,204 shares of the company’s stock, valued at $7,374,341.52. This trade represents a 21.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Pincus & Co. Warburg sold 12,000,000 shares of the firm’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $15.11, for a total transaction of $181,320,000.00. Following the completion of the transaction, the director directly owned 61,822,952 shares in the company, valued at approximately $934,144,804.72. This represents a 16.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 20,126,611 shares of company stock worth $304,273,888. 47.55% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sotera Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UMB Bank n.a. lifted its stake in Sotera Health by 112.8% during the second quarter. UMB Bank n.a. now owns 2,635 shares of the company’s stock worth $29,000 after purchasing an additional 1,397 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Sotera Health by 3,690.1% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,691 shares of the company’s stock worth $31,000 after purchasing an additional 2,620 shares during the last quarter. Parallel Advisors LLC grew its position in Sotera Health by 124.0% in the second quarter. Parallel Advisors LLC now owns 3,340 shares of the company’s stock valued at $37,000 after acquiring an additional 1,849 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Sotera Health by 831.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,288 shares of the company’s stock valued at $37,000 after acquiring an additional 2,935 shares during the last quarter. Finally, Versant Capital Management Inc grew its position in Sotera Health by 117.6% in the third quarter. Versant Capital Management Inc now owns 2,535 shares of the company’s stock valued at $40,000 after acquiring an additional 1,370 shares during the last quarter. 91.03% of the stock is currently owned by institutional investors.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.